Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cpp-115 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 3/20 | 0.96 |
| ▸ | OAT | P04181 | 1/20 | 0.64 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.37 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.32 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cpp-115 Free Base SCHEMBL15142226 | 1.00 | ABAT (0.96) | ABATOATGABRR1SLC6A12SLC6A11 | |
| Cpp-115 Free Base SCHEMBL2411394 | 0.98 | ABAT (1.00) | ABATOATGABRR1SLC6A12SLC6A11 | |
| Cpp-115 Free Base SCHEMBL21404893 | 0.98 | ABAT (1.00) | ABATOATGABRR1SLC6A12SLC6A11 | |
| Cpp-115 Free Base SCHEMBL12258069 | 0.98 | ABAT (1.00) | ABATOATGABRR1SLC6A12SLC6A11 | |
| Cpp-115 Free Base SCHEMBL2408171 | 0.98 | ABAT (1.00) | ABATOATGABRR1SLC6A12SLC6A11 | |
| Cpp-115 Free Base SCHEMBL2407298 | 0.98 | ABAT (1.00) | ABATOATGABRR1SLC6A12SLC6A11 | |
| Hydrochloric Acid SCHEMBL22440735 | 0.80 | OAT (0.97) | ABATOATGABRR1 | |
| SCHEMBL17742869 | 0.80 | ABAT (0.69) | ABATOATGABRR1SLC6A12SLC6A11 | |
| SCHEMBL29318645 | 0.79 | ABAT (0.68) | ABATOATGABRR1PLGPLAT | |
| SCHEMBL29317652 | 0.79 | ABAT (0.68) | ABATOATGABRR1PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151316-A1 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | CATALYST PHARMACEUTICAL PARTNERS | 2016-06-02 | — | — | US | disclosed |
| US-20160151316-A1 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | CATALYST PHARMACEUTICAL PARTNERS | 2016-06-02 | — | — | US | disclosed |
| US-9254274-B2 | Method of treating Tourette'S disorder with GABA-aminotransferase inactivators | CATALYST PHARMACEUTICAL PARTNERS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9254274-B2 | Method of treating Tourette'S disorder with GABA-aminotransferase inactivators | CATALYST PHARMACEUTICAL PARTNERS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-8969413-B2 | Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid | CATALYST PHARMACEUTICAL PARTNERS (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2806867-A1 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | Catalyst Pharmaceutical Partners, Inc. (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2806867-A1 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | Catalyst Pharmaceutical Partners, Inc. (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8895313-B2 | Ligands for aggregated tau molecules | WISTA LABORATORIES LTD. (SG) | 2014-11-25 | — | — | US | disclosed |
| US-20140336256-A1 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | CATALYST PHARMACEUTICAL PARTNERS | 2014-11-13 | — | — | US | disclosed |
| US-20140336256-A1 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | CATALYST PHARMACEUTICAL PARTNERS | 2014-11-13 | — | — | US | disclosed |
| WO-2013112363-A1 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | CATALYST PHARMACEUTICAL PARTNERS (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013112363-A1 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | CATALYST PHARMACEUTICAL PARTNERS (US) | 2013-08-01 | — | — | WO | disclosed |
| US-20130041028-A1 | METHODS OF USING (1S,3S)-3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID | NORTHWESTERN UNIVERSITY (US) | 2013-02-14 | — | — | US | disclosed |